Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Candel Therapeutics (CADL) has provided an update.
Candel Therapeutics, Inc. recently received Orphan Drug Designation from the FDA for their CAN-2409 drug, aimed at treating pancreatic cancer. This special status could provide developmental benefits and market exclusivity, potentially making it a noteworthy consideration for investors tracking advancements in cancer therapies and biotech sector opportunities.
For detailed information about CADL stock, go to TipRanks’ Stock Analysis page.
